---
title: "Arthex Biotech's ATX-01 promising for DM1 per American Journal of Human Genetics; miR-23b target shows benefits."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276854985.md"
description: "New findings suggest that miR-23b could be a crucial target in treating DM1, with research revealing its disease-modifying potential. The study conducted in Valencia, Spain on Feb. 25, 2026, showcases the improved muscle delivery and functional advantages of ATX-01. Arthex Biotech, a prominent biotechnology firm specializing in RNA-based therapeutics, is spearheading these revolutionary advancements. The data points towards miR-23b as a significant player in combating DM1, with promising implications for future treatment strategies."
datetime: "2026-02-25T08:03:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276854985.md)
  - [en](https://longbridge.com/en/news/276854985.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276854985.md)
---

# Arthex Biotech's ATX-01 promising for DM1 per American Journal of Human Genetics; miR-23b target shows benefits.

New findings suggest that miR-23b could be a crucial target in treating DM1, with research revealing its disease-modifying potential. The study conducted in Valencia, Spain on Feb. 25, 2026, showcases the improved muscle delivery and functional advantages of ATX-01. Arthex Biotech, a prominent biotechnology firm specializing in RNA-based therapeutics, is spearheading these revolutionary advancements. The data points towards miR-23b as a significant player in combating DM1, with promising implications for future treatment strategies.

### Related Stocks

- [000863.CN](https://longbridge.com/en/quote/000863.CN.md)
- [ARTHQ.US](https://longbridge.com/en/quote/ARTHQ.US.md)
- [ARTH.US](https://longbridge.com/en/quote/ARTH.US.md)
- [JYB.US](https://longbridge.com/en/quote/JYB.US.md)

## Related News & Research

- [03:50 ETCS Analytical Announces Major Laboratory Expansion](https://longbridge.com/en/news/285041663.md)
- [11:43 ETHM Hospitales e Huawei lanciano insieme il Global Smart Healthcare Showcase](https://longbridge.com/en/news/278140159.md)
- [15:50 ETmiraDry® Reports 55% Growth in Patient Spend, Significantly Outpacing Aesthetic Energy-Based Device Market, and Kicks Off Odor Awareness Week](https://longbridge.com/en/news/283394458.md)
- [09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy](https://longbridge.com/en/news/281030940.md)
- [Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide](https://longbridge.com/en/news/279932014.md)